This inventor holds 2 USPTO granted patents. Top assignee: Cantab Pharmaceuticals Research Limited. Active years: 1999-2000.
Company Filing History:
Years Active: 1999-2000
Title: A Profile of Inventor Henry Stephen Thompson
Introduction: Henry Stephen Thompson, based in Cambridge, GB, is a noteworthy inventor recognized for his contributions to the field of immunotherapy. With two significant patents to his name, he has made a lasting impact in enhancing vaccine technology, particularly concerning human papillomavirus (HPV).
Latest Patents: Thompson's latest patents revolve around polypeptides that serve as immunotherapeutic agents. His work focuses on fusion polypeptides and aggregates of polypeptides comprising papillomavirus-derived antigens. These innovations include compositions designed to work with adjuvants for immunogenic and vaccine purposes. His approach is notable for enabling the elicitation of HPV-specific immune responses. The polypeptides he has developed can be purified to form aggregates capable of passing through sterilization filters when in solution or dispersion, and exist in amorphous aggregates. A specific example of his work is the fusion protein combining HPV proteins L2 and E7.
Career Highlights: Henry Stephen Thompson is associated with Cantab Pharmaceuticals Research Limited, where he has applied his expertise to pioneering research in therapeutic agents. His tenure at the company underscores a commitment to advancing scientific knowledge and practical applications within immunotherapy.
Collaborations: Throughout his career, Thompson has worked alongside esteemed colleagues such as Nigel Richard Whittle and Jeremy Paddon Carmichael. These collaborations enhance the collective expertise within the team and contribute to innovative developments in their field.
Conclusion: Henry Stephen Thompson stands out as a significant figure in the realm of immunotherapeutic innovations. With a keen focus on HPV-related therapies, his patents illustrate a profound understanding of biomedicine and a commitment to improving public health outcomes. His work at Cantab Pharmaceuticals Research Limited and collaborations with talented professionals mark him as an influential inventor whose contributions will be felt for years to come.